This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction뇌경색증을 유발하지 않은 뇌전동맥의 폐쇄 및 협착

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I65 (Occlusion and stenosis of precerebral arteries not resulting in cerebral infarction) | Special Copayment Reduction: V191 (cerebrovascular disease special copayment reduction: 5% copayment for up to 30 days from the registration date)
B. SynonymsCarotid artery stenosis, vertebral artery stenosis, basilar artery stenosis, extracranial carotid artery disease
C. Adult onsetOccurs mainly in people aged 50 or older due to atherosclerosis; it is often discovered without symptoms, but as a precursor lesion of cerebral infarction it requires active management.
1. HistoryMajor advances in the treatment of cerebrovascular disease have been made, from DeBakey's development of carotid endarterectomy in 1954 to carotid ultrasound screening and the introduction of stenting.
2. CausesAtherosclerosis is the most common cause; vascular dissection, fibromuscular dysplasia, Takayasu arteritis, and stenosis after radiation therapy are also causes.
3. GeneticsAtherosclerosis-related genes (LDLR, APOE, PCSK9) and vascular structure genes (FBN1, ELN, COL3A1) contribute to susceptibility to precerebral artery stenosis.
4. General epidemiologyAsymptomatic carotid stenosis (50% or more) is observed in about 7–10% of adults aged 65 or older, and the annual stroke risk of symptomatic stenosis is about 5–10%.
5. PathophysiologyAtherosclerotic plaque formation, rupture of unstable plaque, thrombus formation, distal embolism, or hemodynamic hypoperfusion causes cerebral ischemia.
6. SymptomsMay be asymptomatic or present with transient neurological symptoms in the form of transient ischemic attack (TIA), and a carotid bruit may be heard.
7. SignsCarotid bruit on neck auscultation, retinal artery emboli (Hollenhorst plaque) on fundoscopy, and subtle deficits on neurological examination may be observed.
8. ScreeningCarotid ultrasound is useful for screening high-risk groups and evaluates carotid intima-media thickness (IMT) and the presence of atherosclerotic plaque.
9. DiagnosisThe degree of stenosis, plaque characteristics, and hemodynamic significance are evaluated with carotid duplex ultrasound, MRA, CTA, and DSA.
10. TreatmentRisk factor control, antiplatelet agents, and statins are the foundation, and carotid endarterectomy or stenting is recommended for symptomatic stenosis of 70% or more.
11. PrognosisWith appropriate medical treatment, the annual stroke risk of asymptomatic stenosis is less than 1%, and for symptomatic stenosis, early treatment can greatly reduce the risk of recurrence.
12. PreventionSmoking cessation, control of hypertension, diabetes, and hyperlipidemia, regular exercise, and a healthy diet are key to preventing stenosis by suppressing atherosclerosis.
13. ReferencesNorth American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients. NEJM. 1991 … and 9 other papers

1. History

Clinical recognition of occlusion and stenosis of the precerebral arteries (the extracranial carotid and vertebral arteries) gained momentum from the mid-20th century. The association between carotid stenosis and stroke was first systematically described in 1951 when Miller Fisher proposed the hypothesis that atherosclerotic plaque forms in the carotid intima and thrombi embolize distally to cause stroke. Fisher's work laid the foundation for the understanding that carotid stenosis causes stroke not simply as a hemodynamic narrowing but through an embolic mechanism.

The history of cerebrovascular surgery began in 1953 when Michael DeBakey successfully performed the first carotid endarterectomy (CEA). Initially, surgical risk was high and patient selection was difficult, but with advances in imaging technology and improvements in surgical techniques, CEA began to be established as the standard treatment for symptomatic carotid stenosis in the 1970s–80s. NASCET (North American Symptomatic Carotid Endarterectomy Trial) and ECST (European Carotid Surgery Trial), published in 1991, demonstrated in large randomized controlled trials that CEA significantly lowered the 5-year risk of recurrent stroke compared with medical treatment in symptomatic 70–99% carotid stenosis, playing a decisive role in establishing the evidence base for CEA.

In the 1990s, as carotid duplex ultrasound spread as a noninvasive screening test, the epidemiology of asymptomatic carotid stenosis began to be studied systematically. The 1995 ACAS (Asymptomatic Carotid Atherosclerosis Study) showed that CEA could lower the 5-year stroke risk compared with medical treatment even in asymptomatic 60–99% carotid stenosis. Since the 2000s, carotid artery stenting (CAS) has begun to be applied clinically as an alternative to CEA in patients unresponsive to medical treatment or at high surgical risk, and the effects of CAS and CEA have been compared in studies such as CREST (Carotid Revascularization Endarterectomy versus Stenting Trial). Recently, study results have suggested that aggressive medical treatment alone (statins, antiplatelet agents, hypertension treatment) greatly improves the prognosis of asymptomatic carotid stenosis, prompting reassessment of the indications for prophylactic surgery in asymptomatic stenosis.


2. Causes

The most common cause of occlusion and stenosis of the precerebral arteries is atherosclerosis. Atherosclerosis occurs most commonly at the carotid bifurcation (internal carotid artery origin), because endothelial dysfunction due to flow separation and low shear stress promotes plaque formation. Major risk factors for atherosclerotic carotid stenosis include hypertension (the most important), smoking, diabetes, hyperlipidemia, advanced age, obesity, and physical inactivity. Vertebral artery stenosis occurs predominantly at the origin from the subclavian artery (subclavian artery origin) and at the intracranial entry point.

Arterial dissection is an important cause of precerebral artery stenosis or occlusion, especially in young patients. A tear in the intima of the carotid or vertebral artery allows blood to enter the vessel wall and form an intramural hematoma, and the resulting vascular stenosis or thromboembolism causes stroke. Spontaneous dissection is often associated with vessel wall fragility due to connective tissue disorders (Marfan syndrome, Ehlers-Danlos syndrome type IV, fibromuscular dysplasia), and traumatic dissection can occur after cervical spine manipulation (chiropractic manipulation), traffic accidents, or sports injuries.

Fibromuscular dysplasia (FMD) is a nonatherosclerotic, noninflammatory vascular disease that commonly affects the carotid and vertebral arteries and shows a characteristic 'string of beads' appearance on angiography. It occurs mainly in middle-aged women and is associated with headache, TIA, and arterial dissection. Takayasu arteritis is a granulomatous vasculitis involving large vessels and causes stenosis and occlusion of large vessels, including the carotid, vertebral, and subclavian arteries. Post-radiation stenosis of the extracranial carotid artery, infiltration by carotid body tumor, and stenosis after rupture of a renal artery aneurysm have also been reported as rare causes.


3. Genetics

The genetic background of atherosclerosis, the main cause of precerebral artery stenosis, is a complex polygenic trait. Familial hypercholesterolemia (FH) is caused by mutations in the LDLR, APOB, and PCSK9 genes and is a strong genetic cause of premature atherosclerosis. In FH patients with extremely high LDL cholesterol, carotid plaque formation and stenosis occur early. The APOE ε4 allele is associated with elevated LDL cholesterol and atherosclerosis progression, increasing the risk of carotid stenosis.

The genetic background of fibromuscular dysplasia is being revealed in some familial cases. The rs9349379 variant of the PHACTR1 gene (phosphatase and actin regulator 1) shows a strong association with FMD and cervical artery dissection and is presumed to be involved in vascular smooth muscle cell function and vessel wall integrity. Connective tissue disorder-related genes (FBN1: Marfan syndrome, COL3A1: Ehlers-Danlos syndrome type IV, ELN: elastin arteriopathy) cause structural vessel wall fragility, increasing the risk of spontaneous arterial dissection.

As genetic predisposition to Takayasu arteritis, HLA-B*52:01 (particularly in Asian populations) is the most strongly associated genetic factor, and polymorphisms in genes such as IL12B, MLX, and FCGR2A/FCGR3A also contribute to susceptibility. Hypertension-promoting genes (AGT, ACE, CYP11B2, etc.) contribute indirectly to the risk of atherosclerotic carotid stenosis. Polymorphisms in platelet function-related genes (PTGIS, GP1BA) and coagulation factor genes are also associated with thrombus formation and affect the risk of stroke at the stenotic site.


4. General epidemiology

The prevalence of asymptomatic carotid stenosis (50% or more) increases greatly with age, at about 7–10% of adults aged 65 or older and over 15% in those aged 75 or older. By sex, men show a prevalence 1.5–2 times higher than women. Prevalence is markedly higher in groups with multiple atherosclerotic risk factors such as smoking, hypertension, diabetes, and hyperlipidemia. Korean epidemiological data also report that the prevalence of carotid plaque reaches about 40–60% in older adults aged 65 or older, and significant stenosis (50% or more) is at a level of 5–10%.

Symptomatic carotid stenosis is diagnosed after TIA or minor stroke, and in this case the risk of recurrent stroke within the first 90 days is very high, at about 15–20%. In particular, the first 2 weeks after symptom onset is the period of highest recurrence risk, so early diagnosis and treatment are decisive. In asymptomatic carotid stenosis (60–99%), the annual stroke rate under modern medical treatment is about 0.5–1%, markedly lower than in the past. This is attributed to the widespread use of statin therapy, antiplatelet agents, and hypertension treatment. Vertebral artery stenosis has been studied less than carotid stenosis, but intracranial vertebral and basilar artery stenosis shows a higher prevalence in East Asian populations and is an important cause of posterior circulation TIA and stroke.

The prevalence of fibromuscular dysplasia (FMD) is estimated at about 1–2 per 10,000 population, but it is often underdiagnosed. FMD occurs mainly in women in their 40s to 60s, and the carotid arteries (60–75%) and vertebral arteries are the main sites. The annual incidence of Takayasu arteritis is rare, at about 1–3 per 1,000,000 population, but a relatively high prevalence is reported in Asian countries.


5. Pathophysiology

The mechanisms of cerebral ischemia due to precerebral artery stenosis are broadly divided into two. The first is the embolic mechanism, in which a vulnerable plaque of the carotid or vertebral artery ruptures and platelet thrombi or cholesterol crystals are released distally, occluding cerebral or retinal vessels. In this case it is often classified as I63 (cerebral infarction) or G45 (TIA) rather than I65 (stenosis confirmed without cerebral infarction), but it may be coded as I65 when the embolus lyses spontaneously or is compensated by collateral circulation.

The second is the hemodynamic mechanism, in which severe stenosis (70% or more) lowers distal cerebral perfusion pressure, and when additional hemodynamic stress such as a drop in blood pressure or reduced cardiac output is applied, cerebral perfusion falls below a critical level and border zone ischemia (watershed ischemia) occurs. This presents as TIA or border zone infarction, and with vertebral artery stenosis in particular, subclavian steal syndrome (during upper limb exercise, the subclavian artery steals blood flow, reducing cerebral perfusion) may also occur.

The key elements of atherosclerotic plaque destabilization are infiltration of the lipid core by inflammatory cells (especially macrophages), weakening of the fibrous cap by matrix metalloproteinases (MMPs), and intraplaque hemorrhage due to plaque neovascularization. Plaque characterization MRI has confirmed that unstable plaques with hemorrhage (type VI plaque) carry a markedly higher stroke risk than stable plaques, so plaque characteristics may be more important than the simple degree of stenosis in treatment decisions. Endothelial dysfunction, platelet activation, and hypercoagulability promote thrombus formation at the stenotic site, which can progress to complete occlusion.


6. Symptoms

Patients with precerebral artery stenosis classified as I65 by definition have no confirmed cerebral infarction, so this applies to cases that are asymptomatic (asymptomatic stenosis) or present with transient, reversible neurological symptoms equivalent to a transient ischemic attack (TIA). Asymptomatic carotid stenosis is often discovered incidentally on neck auscultation or on carotid ultrasound or neck MRI performed for other purposes.

TIA symptoms in symptomatic carotid stenosis are characterized by neurological deficits corresponding to the carotid territory that resolve completely within 24 hours. The most characteristic symptom of TIA of internal carotid artery origin is amaurosis fugax (transient monocular blindness), in which a transient scotoma develops in the ipsilateral eye and resolves within minutes; it is caused by embolism to the ophthalmic artery. Other symptoms may include contralateral unilateral weakness, sensory abnormalities, and speech disturbance. In TIA due to vertebral artery stenosis, vertigo, nausea, vomiting, diplopia, gait ataxia, and unilateral or bilateral motor and sensory abnormalities occur, and in some cases the chief complaint is nonspecific systemic symptoms that are difficult to characterize.

In subclavian steal syndrome, posterior circulation ischemic symptoms such as dizziness, presyncope, visual disturbance, and gait disturbance appear intermittently during upper limb exercise (raising the arm, gripping). A difference of 15 mmHg or more in blood pressure between the two arms suggests subclavian artery stenosis. Stenosis due to Takayasu arteritis is accompanied by systemic symptoms (fever, weight loss, fatigue), neck pain, upper limb claudication, and decreased pulses, suggesting systemic vasculitis.


7. Signs

On physical examination, the most important sign of carotid stenosis is a carotid bruit. A high-pitched systolic bruit heard at the carotid bifurcation on auscultation of the neck is due to turbulent flow and suggests significant carotid stenosis. However, the absence of a bruit does not exclude stenosis (especially in severe stenosis or complete occlusion, there may be no bruit), and the presence of a bruit does not necessarily mean significant stenosis. In subclavian steal syndrome, a difference in blood pressure between the arms (>15 mmHg) and a decreased or absent ulnar pulse are characteristic.

On ophthalmologic examination, a Hollenhorst plaque is a cholesterol crystal released from a carotid atherosclerotic plaque that is lodged in a retinal artery (especially at a bifurcation), appearing on fundoscopy as a golden or white refractile intravascular lesion. Finding a Hollenhorst plaque is strong indirect evidence of ipsilateral carotid stenosis and requires immediate carotid evaluation. In Takayasu arteritis, blood pressure differences between the upper and lower limbs, pulselessness, and vascular bruits are observed in multiple vascular territories.

Neurological examination is normal when there is no permanent deficit after TIA, but careful examination sometimes reveals cognitive decline (white matter lesions due to chronic hypoperfusion), subtle motor asymmetry, and reflex changes. The ABCD2 score (age, blood pressure, clinical features, duration of symptoms, diabetes) is used to stratify stroke risk after TIA and determine the urgency of treatment. It is important to evaluate both the degree of vascular stenosis and plaque morphology (calcified, soft, ulcerated) with carotid ultrasound.


8. Screening

General population screening for asymptomatic carotid stenosis is not recommended in most current guidelines. However, targeted screening of high-risk groups is clinically meaningful. Screening by carotid duplex ultrasound is considered when a carotid bruit is heard, in patients with lower extremity atherosclerosis (peripheral artery disease) or coronary artery disease, or in people aged 65 or older with a combination of hypertension, diabetes, smoking, and hyperlipidemia. Measurement of carotid intima-media thickness (IMT) noninvasively evaluates the degree of atherosclerosis, and when IMT is thickened or plaque is found, aggressive risk factor management is started.

In patients at high cardiovascular risk (high ASCVD risk), in addition to carotid ultrasound, peripheral artery disease is evaluated simultaneously by measuring the ankle-brachial index (ABI), and the systemic atherosclerotic burden is determined. Screening for vertebral artery stenosis is mainly performed when clinically suspected after posterior circulation TIA or stroke; the origin is evaluated by ultrasound and intracranial extension is confirmed by MRA or CTA. In young female patients with suspected fibromuscular dysplasia, noninvasive vascular evaluation by neck MRA or CTA is useful. When Takayasu arteritis is suspected, systemic vascular evaluation by CTA or MRA is needed.

After TIA or minor stroke, it is essential to perform carotid ultrasound or vascular imaging within 24–72 hours to identify treatable stenosis early. A TIA clinic is an effective structure for such urgent evaluation.


9. Diagnosis

In the diagnosis of precerebral artery stenosis, carotid duplex ultrasound is the first noninvasive test performed. Combining B-mode ultrasound with Doppler flow measurement, it evaluates the degree of diameter stenosis, flow velocity (reflecting the degree of stenosis), and plaque characteristics (echogenicity, surface irregularity, ulceration). A PSV (peak systolic velocity) >125 cm/s suggests 50% or more stenosis, and >230 cm/s suggests 70% or more. Calculation of the degree of stenosis by the NASCET criteria is used for treatment decisions.

MR angiography (MRA) and CT angiography (CTA) are used to confirm ultrasound results or to extend the evaluation to the intracranial arteries and the vertebrobasilar system. CTA can accurately assess the degree of calcification and stenosis and allows rapid examination, although it involves radiation exposure. MRA can be performed without contrast, and adding high-resolution vessel wall imaging (vessel wall MRI) allows assessment of plaque characteristics such as intraplaque hemorrhage, lipid core, and fibrous cap thickness, which is useful for distinguishing unstable plaques.

Digital subtraction angiography (DSA) is invasive but has the highest resolution, allowing final evaluation of vascular anatomy and endovascular treatment at the same time. It is essential when planning carotid stenting or angioplasty. Soft lipid-rich plaques and calcified plaques can be distinguished by measuring the CT attenuation values (HU) of plaques. In Takayasu arteritis, evaluation of vascular inflammatory activity by serum CRP, ESR, and whole-body PET-CT is performed concurrently.


10. Treatment

Treatment of precerebral artery stenosis is divided into medical treatment and revascularization. Medical treatment is the basic treatment applied to all patients with stenosis. Statins lower stroke risk by reducing LDL cholesterol to below 70 mg/dL and through plaque-stabilizing effects. Antiplatelet agents (aspirin or clopidogrel) are essential for preventing thromboembolism in patients with symptomatic stenosis. Recently, short-term dual antiplatelet therapy (DAPT, aspirin + clopidogrel for 21 days) has been proven more effective than monotherapy in preventing recurrence immediately after TIA or minor stroke. Treatment of hypertension (target systolic blood pressure below 130 mmHg), diabetes control, and smoking cessation education are also key elements of risk factor management.

Carotid endarterectomy (CEA) is the standard treatment for symptomatic carotid stenosis (70–99%), and early CEA performed within 2 weeks of symptom onset is most effective in preventing recurrence. In the NASCET study, CEA for 70–99% stenosis lowered the 5-year stroke rate from 26% to 9%. It is also effective in some patients with 50–69% stenosis, but the benefit is small, and surgical benefit has not been demonstrated for stenosis below 50%. The ECST-2 and CREST-2 studies comparing modern medical treatment with CEA in asymptomatic 60–99% carotid stenosis are underway, and the possibility has been raised that the previous benefit of CEA has been considerably reduced by modern medical treatment.

Carotid artery stenting (CAS) is considered as an alternative to CEA in patients at high surgical risk (severe cardiopulmonary disease, history of prior neck radiation therapy, repeat ipsilateral CEA, anatomically high-risk carotid artery). In the CREST study, the composite outcomes (stroke, myocardial infarction, death) of CAS and CEA were similar, but stroke was relatively more frequent and myocardial infarction less frequent with CAS. Use of an embolic protection device (EPD) is recommended during CAS. Revascularization (stenting) for vertebral artery stenosis is considered when symptomatic, but the evidence is limited. In Takayasu arteritis, immunosuppressive treatment (steroids, methotrexate, biologics) is the foundation, and revascularization of stenoses is considered in the stable phase.


11. Prognosis

The prognosis of precerebral artery stenosis varies greatly with the presence of symptoms and the degree of stenosis. In symptomatic carotid stenosis (70–99%), the 2-year stroke rate without appropriate medical treatment reaches about 26%, but it decreases to about 9% after CEA or CAS. Because stroke risk is highest within the first 48 hours to 2 weeks after symptom onset, prompt initiation of treatment during this period is decisive. In high-risk TIA patients with a high ABCD2 score (≥4 points), early dual antiplatelet therapy and statins should be started immediately.

In asymptomatic carotid stenosis, the annual stroke rate was previously reported to be 2–3%, but under modern medical treatment (statins, antiplatelet agents, hypertension treatment) it has fallen substantially to about 0.5–1% per year. This means that the absolute benefit of prophylactic CEA in asymptomatic stenosis has decreased, and the ECST-2 and CREST-2 studies are currently comparing this directly. Unstable plaque (hemorrhage, irregular surface, lipid core), contralateral carotid stenosis or occlusion, and reduced intracranial hemodynamic reserve (low CVR) are high-risk prognostic factors in asymptomatic stenosis.

Fibromuscular dysplasia has a favorable prognosis when appropriate treatment (antiplatelet agents, angioplasty) is received after diagnosis. Takayasu arteritis has a high relapse rate and requires long-term immunosuppressive treatment, as well as ongoing follow-up to prevent progression of vascular stenosis and ischemic complications. The incidence of in-stent restenosis after carotid stenting is about 5–10%, and in case of restenosis, revascularization or medical treatment is considered.


12. Prevention

Primary prevention of precerebral artery stenosis is suppressing the development of atherosclerosis. Smoking cessation is the single most effective action for preventing carotid stenosis, slowing atherosclerosis progression and reducing platelet aggregation. Treatment of hypertension suppresses endothelial injury and the promotion of atherosclerosis, slowing the progression of carotid IMT. Statin therapy stabilizes and reduces the size of atherosclerotic plaques and is recommended for prophylactic use in high-risk groups. Diabetes control (HbA1c below 7%) and treatment of dyslipidemia (LDL below 70 mg/dL) also contribute to slowing the progression of carotid atherosclerosis.

The Mediterranean diet was proven effective in preventing cardiovascular disease in the PREDIMED study; this diet, rich in olive oil and nuts, suppresses LDL oxidation and atherosclerosis progression. Regular aerobic exercise (150 minutes or more per week) contributes to preventing carotid atherosclerosis through blood pressure control, improved lipid profile, and enhanced endothelial function. In obese patients, weight loss has combined positive effects on blood pressure, blood glucose, and lipids.

In patients with already confirmed stenosis, the key to secondary prevention is intensified medical treatment together with monitoring of stenosis progression through regular carotid ultrasound follow-up. If the degree of stenosis increases or a clinical TIA occurs, immediate reassessment and redetermination of the treatment plan are needed. In nonatherosclerotic stenosis such as fibromuscular dysplasia, the role of statins is limited, and antiplatelet agents and angioplasty are the main means of prevention and treatment.


13. References

  1. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325(7):445-453. DOI: 10.1056/NEJM199108153250701. PMID: 1852179.

  2. Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11-23. DOI: 10.1056/NEJMoa0912321. PMID: 20505173.

  3. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369(9558):283-292. DOI: 10.1016/S0140-6736(07)60150-0. PMID: 17258668.

  4. Halliday A, Harrison M, Hayter E, et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet. 2010;376(9746):1074-1084. DOI: 10.1016/S0140-6736(10)61197-X. PMID: 20870099.

  5. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014;45(7):2160-2236. DOI: 10.1161/STR.0000000000000024. PMID: 24788967.

  6. Naylor AR, Ricco JB, de Borst GJ, et al. Editor's choice - management of atherosclerotic carotid and vertebral artery disease: 2017 clinical practice guidelines of the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg. 2018;55(1):3-81. DOI: 10.1016/j.ejvs.2017.06.021. PMID: 28851594.

  7. de Waard DD, Verhoeven JI, Dankbaar JW, et al. Prevalence and clinical relevance of carotid stenosis as incidental finding on routine MRI: a systematic review. Stroke Vasc Neurol. 2020;5(1):65-71. DOI: 10.1136/svn-2019-000252. PMID: 32411450.

  8. Paraskevas KI, Mikhailidis DP, Veith FJ, Spence JD. Definition of best medical treatment in asymptomatic and symptomatic carotid artery stenosis. Angiology. 2016;67(5):411-419. DOI: 10.1177/0003319715596157. PMID: 26271048.

  9. Mohr JP, Albers GW, Amarenco P, et al. American Heart Association Prevention Conference IV: Prevention and Rehabilitation of Stroke: Etiology of stroke. Stroke. 1997;28(7):1501-1506. DOI: 10.1161/01.STR.28.7.1501. PMID: 9227702.

  10. Kim SM, Jung JM, Oh MK, et al. Carotid artery atherosclerosis in Korea: a population-based study using duplex ultrasound. J Korean Med Sci. 2018;33(23):e166. DOI: 10.3346/jkms.2018.33.e166. PMID: 29805264.